Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
Novel high throughput functional approach to investigate the cellular basis of sex-dependent differences in chemotherapy-induced peripheral neuropathy (CIPN) in primary dorsal root ganglia (DRG) and using cannabidiol (CBD) as a potential molecular treatment against CIPN-induced allodynia.
EF 2021-22
Résumé
Chronic pain is a defining feature of many conditions, including chemotherapy-induced peripheral neuropathy (CIPN). There are currently no effective treatments for chronic pain, and many are highly addictive. Thus, pain remains an unmet medical need. Epidemiological studies have long implicated sexual dimorphism in chronic pain patients which disproportionately affects females. An immense body of published research suggests that this could be driven, in part, by a partially distinct pain biology between males and females. Specifically, females treated with a common chemotherapy agent, paclitaxel, experience a more profound neuropathic response to cold temperatures than males. This proposal seeks to first, investigate whether the difference in experiencing CIPN between the sexes has molecular components at the sensory neuronal level. Second, to investigate the therapeutic potential of a promising compound that is isolated from the cannabis plant, cannabidiol (CBD), against CIPN, at a molecular level. This work will rigorously determine if there are biological sex differences in pain sensation at the sensory level, and whether, at this level, chemotherapy modulates pain biology sex-dependently. When possible, we will investigate these effects in human pain-sensing neurons, which may lay the foundation for future clinical trials. To achieve these objectives, we are developing a paradigm-shifting high throughput methodology to functionally assess excitability properties of sensory neurons and the underlying contributions of ion channels in the same neuron. These findings will collectively result in major leaps in key areas that impact both Canada and the rest of the world at large, including chronic pain differences among male and female populations, enhancing CIPN treatment benefiting cancer patients, and potentially finding an alternative drug to existing addictive treatments for pain.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Connecticut, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
453928
Name
Ghovanloo Mohammad-Reza
Region
Connecticut
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Novel high throughput functional approach to investigate the cellular basis of sex-dependent differences in chemotherapy-induced peripheral neuropathy (CIPN) in primary dorsal root ganglia (DRG) and using cannabidiol (CBD) as a potential molecular treatment against CIPN-induced allodynia.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Cannabidiol; Chemotherapy Induced Peripheral Neuropathy; Electrophysiology; Excitability; Ion Channel; Neuropathy; Pain; Patch-Clamp; Sex-Dependence; Sodium Channel
Abstract
Chronic pain is a defining feature of many conditions, including chemotherapy-induced peripheral neuropathy (CIPN). There are currently no effective treatments for chronic pain, and many are highly addictive. Thus, pain remains an unmet medical need. Epidemiological studies have long implicated sexual dimorphism in chronic pain patients which disproportionately affects females. An immense body of published research suggests that this could be driven, in part, by a partially distinct pain biology between males and females. Specifically, females treated with a common chemotherapy agent, paclitaxel, experience a more profound neuropathic response to cold temperatures than males. This proposal seeks to first, investigate whether the difference in experiencing CIPN between the sexes has molecular components at the sensory neuronal level. Second, to investigate the therapeutic potential of a promising compound that is isolated from the cannabis plant, cannabidiol (CBD), against CIPN, at a molecular level. This work will rigorously determine if there are biological sex differences in pain sensation at the sensory level, and whether, at this level, chemotherapy modulates pain biology sex-dependently. When possible, we will investigate these effects in human pain-sensing neurons, which may lay the foundation for future clinical trials. To achieve these objectives, we are developing a paradigm-shifting high throughput methodology to functionally assess excitability properties of sensory neurons and the underlying contributions of ion channels in the same neuron. These findings will collectively result in major leaps in key areas that impact both Canada and the rest of the world at large, including chronic pain differences among male and female populations, enhancing CIPN treatment benefiting cancer patients, and potentially finding an alternative drug to existing addictive treatments for pain.
Competitiondate
202109
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ghovanloo, Mohammad-Reza
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~